Zoetis R&D chief Catherine Knupp to retire; Robert Polzer named successor effective Jan 1, 2022

Zoetis Inc.

Dr. Catherine Knupp will retire as EVP & President of R&D effective Dec 31, 2021.
Robert J. Polzer, current SVP of Global Therapeutics, appointed EVP & President of R&D effective Jan 1, 2022.
Polzer will report to CEO Kristin Peck and join the Zoetis Executive team.
Knupp will remain as advisor through Feb 28, 2022 to assist with transition.
Zoetis highlights over 1,100 new product introductions in the past five years under Knupp's leadership.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert J. Polzer

Executive Vice President and President of Research & Development

ZTS · Zoetis Inc.

Effective: 2022-01-01
Filed: October 18, 2021, 7:59 PM ET

the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022

Departed

Catherine Knupp

Executive Vice President and President of Research & Development

ZTS · Zoetis Inc.

Effective: 2021-12-31
Successor: Robert J. Polzer
Filed: October 18, 2021, 7:59 PM ET

Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert J. Polzer was appointed as Executive Vice President and President of Research & Development at Zoetis Inc..

Action: appointed
Role: Executive Vice President and President of Research & Development

Exact text from the filing

the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine Knupp retired as Executive Vice President and President of Research & Development at Zoetis Inc..

Action: retired
Role: Executive Vice President and President of Research & Development

Exact text from the filing

Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021

View on SEC.gov

Zoetis Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-301194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.